Eli Lilly (LLY)
713.71
-1.49 (-0.21%)
NYSE · Last Trade: May 24th, 7:30 PM EDT
Detailed Quote
Previous Close | 715.20 |
---|---|
Open | 710.00 |
Bid | 714.00 |
Ask | 714.79 |
Day's Range | 709.00 - 719.64 |
52 Week Range | 677.09 - 972.53 |
Volume | 2,642,511 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.84%) |
1 Month Average Volume | 4,821,362 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies
Via MarketBeat · May 23, 2025
Via The Motley Fool · May 23, 2025
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · May 23, 2025
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
Via Stocktwits · May 22, 2025
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound
Via Stocktwits · May 22, 2025
Via Benzinga · May 21, 2025
Despite $6 trillion in promised investments under Trump, Goldman Sachs estimates only $30B–$135B will meaningfully impact U.S. GDP.
Via Benzinga · May 20, 2025
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks.
Via Benzinga · May 20, 2025
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Ireland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.
Via AB Newswire · May 19, 2025
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.
Via Investor's Business Daily · May 19, 2025
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 18, 2025
Via The Motley Fool · May 17, 2025
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts
Via MarketBeat · May 17, 2025